These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9096370)

  • 1. A peptide composed of tandem analogs of two myasthenogenic T cell epitopes interferes with specific autoimmune responses.
    Katz-Levy Y; Paas-Rozner M; Kirshner S; Dayan M; Zisman E; Fridkin M; Wirguin I; Sela M; Mozes E
    Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3200-5. PubMed ID: 9096370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity induced by myasthenogenic T cell epitopes.
    Faber-Elmann A; Paas-Rozner M; Sela M; Mozes E
    Proc Natl Acad Sci U S A; 1998 Nov; 95(24):14320-5. PubMed ID: 9826698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs.
    Katz-Levy Y; Kirshner SL; Sela M; Mozes E
    Proc Natl Acad Sci U S A; 1993 Aug; 90(15):7000-4. PubMed ID: 7688469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide analogs to pathogenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis.
    Zisman E; Katz-Levy Y; Dayan M; Kirshner SL; Paas-Rozner M; Karni A; Abramsky O; Brautbar C; Fridkin M; Sela M; Mozes E
    Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4492-7. PubMed ID: 8633096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice.
    Paas-Rozner M; Dayan M; Paas Y; Changeux JP; Wirguin I; Sela M; Mozes E
    Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2168-73. PubMed ID: 10681457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered peptide ligands of a myasthenogenic epitope as modulators of specific T-cell responses.
    Kirshner SL; Zisman E; Fridkin M; Sela M; Mozes E
    Scand J Immunol; 1996 Nov; 44(5):512-21. PubMed ID: 8947604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Processing requirements of two acetylcholine receptor derived peptides for binding to antigen presenting cells and stimulation of murine T cell lines.
    Zisman E; Mozes E
    Int Immunol; 1994 May; 6(5):683-91. PubMed ID: 7521666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell receptor expression and differential proliferative responses by T cells specific to a myasthenogenic peptide.
    Kirshner SL; Waisman A; Zisman E; Ben-Nun A; Mozes E
    Cell Immunol; 1997 Aug; 180(1):20-8. PubMed ID: 9316635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.
    Paas-Rozner M; Sela M; Mozes E
    Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12642-7. PubMed ID: 11606745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single amino acid analogs of a myasthenogenic peptide modulate specific T cell responses and prevent the induction of experimental autoimmune myasthenia gravis.
    Katz-Levy Y; Dayan M; Wirguin I; Fridkin M; Sela M; Mozes E
    J Neuroimmunol; 1998 May; 85(1):78-86. PubMed ID: 9627000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fine specificity of T cell lines and clones that are capable of inducing autoimmune manifestations in mice.
    Kirshner SL; Katz-Levy Y; Wirguin I; Argov Z; Mozes E
    Cell Immunol; 1994 Aug; 157(1):11-28. PubMed ID: 7518748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An altered peptide ligand inhibits the activities of matrix metalloproteinase-9 and phospholipase C, and inhibits T cell interactions with VCAM-1 induced in vivo by a myasthenogenic T cell epitope.
    Faber-Elmann A; Grabovsky V; Dayan M; Sela M; Alon R; Mozes E
    FASEB J; 2001 Jan; 15(1):187-194. PubMed ID: 11149906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of T cell proliferation specific for acetylcholine receptor epitopes related to myasthenia gravis with antibody to T cell receptor or with competitive synthetic polymers.
    Brocke S; Dayan M; Steinman L; Rothbard J; Mozes E
    Int Immunol; 1990; 2(8):735-42. PubMed ID: 1707306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4+ T cells.
    Paas-Rozner M; Sela M; Mozes E
    Proc Natl Acad Sci U S A; 2003 May; 100(11):6676-81. PubMed ID: 12743364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosis.
    Aruna BV; Ben-David H; Sela M; Mozes E
    Immunology; 2006 Jul; 118(3):413-24. PubMed ID: 16827902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The autoimmune response of different mouse strains to T-cell epitopes of the human acetylcholine receptor alpha subunit.
    Brocke S; Dayan M; Rothbard J; Fuchs S; Mozes E
    Immunology; 1990 Apr; 69(4):495-500. PubMed ID: 1692300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of myasthenogenic responses of a T cell line by a dual altered peptide ligand by induction of CD4+CD25+ regulatory cells.
    Aruna BV; Sela M; Mozes E
    Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10285-90. PubMed ID: 16014414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CD8+CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand.
    Ben-David H; Sharabi A; Dayan M; Sela M; Mozes E
    Proc Natl Acad Sci U S A; 2007 Oct; 104(44):17459-64. PubMed ID: 17956982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct binding of a myasthenia gravis related epitope to MHC class II molecules on living murine antigen-presenting cells.
    Mozes E; Dayan M; Zisman E; Brocke S; Licht A; Pecht I
    EMBO J; 1989 Dec; 8(13):4049-52. PubMed ID: 2480232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine profile and T cell adhesiveness to endothelial selectins: in vivo induction by a myasthenogenic T cell epitope and immunomodulation by a dual altered peptide ligand.
    Faber-Elmann A; Grabovsky V; Dayan M; Sela M; Alon R; Mozes E
    Int Immunol; 2000 Dec; 12(12):1651-8. PubMed ID: 11099304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.